Resource Genomic , Pathway Networ k , and Immunologic Features Distinguishing Squamous Carcinomas Graphical

[1]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[2]  Steven J. M. Jones,et al.  Integrated genomic and molecular characterization of cervical cancer , 2017, Nature.

[3]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[4]  Adam B. Olshen,et al.  Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis , 2009, Bioinform..

[5]  Kevin R. Coombes,et al.  Variable slope normalization of reverse phase protein arrays , 2009, Bioinform..

[6]  C. Van Waes,et al.  Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways , 2016, Clinical Cancer Research.

[7]  R. Jove,et al.  The Src-family kinase Lck can induce STAT3 phosphorylation and DNA binding activity. , 1999, Cellular signalling.

[8]  Julia A. Lasserre,et al.  PROmiRNA: a new miRNA promoter recognition method uncovers the complex regulation of intronic miRNAs , 2013, Genome Biology.

[9]  H. Yeger,et al.  CCN family of proteins: critical modulators of the tumor cell microenvironment , 2016, Journal of Cell Communication and Signaling.

[10]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[11]  R. Neve,et al.  A conditional feedback loop regulates Ras activity through EphA2. , 2005, Cancer cell.

[12]  Hsien-Da Huang,et al.  miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..

[13]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[14]  A. Services,et al.  Integrated genomic and molecular characterization of cervical cancer. , 2017 .

[15]  Jian Sun,et al.  Genetic landscape of esophageal squamous cell carcinoma , 2014, Nature Genetics.

[16]  Benjamin J. Raphael,et al.  Integrated genomic characterization of oesophageal carcinoma , 2017, Nature.

[17]  M. Heinig,et al.  Principles of microRNA Regulation Revealed Through Modeling microRNA Expression Quantitative Trait Loci , 2016, Genetics.

[18]  S. Chi,et al.  Frequent alteration of p63 expression in human primary bladder carcinomas. , 2000, Cancer research.

[19]  D. P. Mishra,et al.  Matrix reloaded: CCN, tenascin and SIBLING group of matricellular proteins in orchestrating cancer hallmark capabilities. , 2016, Pharmacology & therapeutics.

[20]  A. Rustgi,et al.  Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. , 2016, Cancer cell.

[21]  J. Jones.  The Cancer Institute. , 1978, The Australian nurses' journal. Royal Australian Nursing Federation.

[22]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[23]  Yusuke Nakamura,et al.  WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer , 2017, Scientific Reports.

[24]  A. Ashworth,et al.  Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways , 2015, Molecular Cancer Therapeutics.

[25]  K. Coombes,et al.  A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers , 2010, Clinical Proteomics.

[26]  R. Kurzrock,et al.  Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience , 2014, Oncotarget.

[27]  Olivier Gevaert,et al.  MethylMix: an R package for identifying DNA methylation-driven genes , 2015, Bioinform..

[28]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[29]  J. Grilley-Olson,et al.  A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors , 2016, Investigational New Drugs.

[30]  S. Kaech,et al.  TRAF3/CYLD mutations identify a distinct subset of human papillomavirus‐associated head and neck squamous cell carcinoma , 2017, Cancer.

[31]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[32]  L. Liaw,et al.  Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype , 2016, Scientific Reports.

[33]  Gordon B. Mills,et al.  The energy sensing LKB1–AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis , 2007, Nature Cell Biology.

[34]  Simion I. Chiosea,et al.  JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth12 , 2015, Neoplasia.

[35]  A. D’Andrea,et al.  The Fanconi anaemia pathway: new players and new functions , 2016, Nature Reviews Molecular Cell Biology.

[36]  P. Siegel,et al.  5′-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion , 2016, The Journal of cell biology.

[37]  James B. Mitchell,et al.  PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer , 2013, Clinical Cancer Research.

[38]  Chandra Sekhar Pedamallu,et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.

[39]  E. Mendez,et al.  Strategies for Targeted Therapy in Head and Neck Squamous Cell Carcinoma Using WEE1 Inhibitor AZD1775 , 2017, JAMA otolaryngology-- head & neck surgery.

[40]  Dylan M. Marchione,et al.  Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas , 2017, Nature Genetics.

[41]  Rehan Akbani,et al.  A Galaxy Implementation of Next-Generation Clustered Heatmaps for Interactive Exploration of Molecular Profiling Data. , 2017, Cancer research.

[42]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[43]  James D Doecke,et al.  Co-localized genomic regulation of miRNA and mRNA via DNA methylation affects survival in multiple tumor types. , 2016, Cancer genetics.

[44]  S. Varambally,et al.  TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer , 2014, Nature Communications.

[45]  G. Getz,et al.  PathSeq: software to identify or discover microbes by deep sequencing of human tissue , 2011, Nature Biotechnology.

[46]  V. Steele,et al.  Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ , 2015, PloS one.

[47]  G. Mills,et al.  A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma , 2014, Molecular Cancer Therapeutics.

[48]  C. Van Waes,et al.  Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. , 2016, Oral oncology.

[49]  A. Hershko,et al.  Role of CCT chaperonin in the disassembly of mitotic checkpoint complexes , 2017, Proceedings of the National Academy of Sciences.

[50]  David Haussler,et al.  TumorMap: Exploring the Molecular Similarities of Cancer Samples in an Interactive Portal. , 2017, Cancer research.

[51]  Jingpeng Liu,et al.  Transforming growth factor-β1 activates ΔNp63/c-Myc to promote oral squamous cell carcinoma. , 2016, Oral surgery, oral medicine, oral pathology and oral radiology.

[52]  Sridhar Ramaswamy,et al.  ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis. , 2017, Cancer cell.

[53]  G. Raca,et al.  Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma , 2015, Oncotarget.

[54]  M. Brown,et al.  YAP Dysregulation by Phosphorylation or ΔNp63-mediated Gene Repression Promotes Proliferation, Survival and Migration in Head and Neck Cancer Subsets , 2010, Oncogene.

[55]  W. Hung,et al.  Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer , 2017, Oncogenesis.

[56]  J. Pietenpol,et al.  ΔNp63α Expression Is Regulated by the Phosphoinositide 3-Kinase Pathway* , 2003, Journal of Biological Chemistry.

[57]  James B. Mitchell,et al.  SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2. , 2016, Cancer research.

[58]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[59]  M. Obinata,et al.  p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity , 2007, Oncogene.

[60]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[61]  T. Mok,et al.  Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers , 2016, Scientific Reports.

[62]  R. Eckert,et al.  Sulforaphane reduces YAP/∆Np63α signaling to reduce cancer stem cell survival and tumor formation , 2017, Oncotarget.

[63]  L. Lau.  Cell surface receptors for CCN proteins , 2016, Journal of Cell Communication and Signaling.

[64]  H. Ji,et al.  YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation. , 2017, Cancer research.

[65]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[66]  Yiling Lu,et al.  Pharmacodynamic Markers of Perifosine Efficacy , 2007, Clinical Cancer Research.

[67]  J. Asara,et al.  Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1 , 2009, Molecular and Cellular Biology.

[68]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[69]  I. Mani,et al.  Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice. , 2016, Physiological genomics.

[70]  Bo Ram Kim,et al.  Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth* , 2017, Molecular & Cellular Proteomics.

[71]  James B. Mitchell,et al.  Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384 , 2014, Clinical Cancer Research.

[72]  T. Akiyama,et al.  Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3β-mediated phosphorylation of β-catenin , 2008, Oncogene.

[73]  M. Schiffman,et al.  Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: A search for human papillomavirus , 2013, International journal of cancer.

[74]  Yusuke Nakamura,et al.  WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck , 2016, Oncotarget.

[75]  Michel Sadelain,et al.  Safe harbours for the integration of new DNA in the human genome , 2011, Nature Reviews Cancer.

[76]  G. Adelmant,et al.  Fast kinase domain-containing protein 3 is a mitochondrial protein essential for cellular respiration. , 2010, Biochemical and biophysical research communications.

[77]  Z. Siprashvili,et al.  ZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiation. , 2012, Developmental cell.

[78]  K. Coombes,et al.  Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.

[79]  Xuming He,et al.  Non-parametric quantification of protein lysate arrays , 2007, Bioinform..

[80]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[81]  C. Van Waes,et al.  MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma , 2015, Clinical Cancer Research.

[82]  James B. Mitchell,et al.  HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma. , 2013, Translational oncology.

[83]  Chris Sander,et al.  Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. , 2016, Cell reports.